AMR industry alliance
The collective industry voice on antimicrobial resistance
The AMR Industry Alliance is the collective voice of the life sciences sector on antimicrobial resistance. We bring together biotech, diagnostics, generics, and research-based pharmaceutical companies across the antibiotic life cycle, and we advocate for the policy, procurement, and practice changes needed to save lives.
associations
Why AMR Matters
Resistance is outpacing the medicines we have left.
Antimicrobial resistance is one of the top 10 global public health threats, according to the World Health Organization. Drug-resistant infections could directly cause 39 million deaths between 2025 and 2050, and as resistance spreads, the routine care that modern medicine depends on, from surgery to chemotherapy to childbirth, gets harder to deliver safely. The burden falls hardest on low- and middle-income countries, though no country is spared. It also reaches high-income countries, where health systems face shortages of generic antibiotics and limited access to newer medicines. This is a threat the world can still curb, and doing so takes coordinated effort across access and appropriate use, manufacturing, and research, with governments, health systems, and industry working together.
Focus Areas
Three commitments the industry can be measured on.
Access and Appropriate Use
Expanding access to the antibiotics people need and supporting the responsible use that keeps them working.
Manufacturing
Setting and independently certifying a common standard for responsible antibiotic production, so manufacturing does not drive resistance.
Research and Science
Tracking the decline in new antibiotics and backing the incentives needed to rebuild the pipeline.
Key Resources
Reports, standards and evidence
Reports, guidance, and policy positions from across our work.
Report
2024 Year in Review
The Alliance's periodic survey of industry action on AMR.
Download PDF
Manufacturing
Antibiotic Manufacturing Standard
The independently certifiable standard for responsible production.
Download PDF
Declaration
AMR Industry Declaration
The founding commitments Alliance members sign up to.
Download PDF
AMR in Numbers
Why action is urgent
The scale of the threat is clear, and so is the cost of treating it as tomorrow’s problem.
01
deaths drug-resistant infections could directly cause between 2025 and 2050 — around three every minute.
02
AMR’s projected annual loss to global GDP by 2050 without action.
03
of antimicrobial prescriptions worldwide are unnecessary or inappropriate — one of the drivers still within reach to change.
Latest Updates
News from the Alliance
The latest announcements, updates, and perspectives from the Alliance.
Feature
A Decade of Action on AMR: Reflections and Path to 2029
A decade after the Davos Declaration on AMR, sustained collaboration has driven innovation, strengthened stewardship, and expanded access to lifesaving antibiotics and diagnostics....
Get in touch
Whether you’re a member, a partner, or exploring how to engage,
we’d like to hear from you.